APRIL 15, 2011 -- PART 1: ACHIEVEMENTS OF THE PAST YEAR
The second Sage Bionetworks Commons Congress will be held in San Francisco on April 15-16, 2011. The theme will be the move towards personalized, patient-driven medicine, and the role that Sage Bionetworks can play in that transition. Expect reports from the Sage Federation, Working Groups, and exciting projects like SageCite, poster sessions and evening activities.
A patient perspective on healthcare followed by summaries of the new projects that have emerged since the 2010 Congress as a demonstration that the efforts of the Commons over the past year have paid off. The Federation, the Commons Platform, Repository and independent projects like SageCite will be featured. Sage Bionetworks will review its own internal development work and a new journal for sharing models will be announced.
Eric Schadt, PhD, is Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences, and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai. Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. He has published more than 200 peer-reviewed papers in leading scientific journals, and contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Dr. Schadt is also a founding member of Sage Bionetworks, an open-access genomics initiative designed to build and support databases and an accessible platform for creating innovative dynamic disease models. Prior to joining Mount Sinai in 2011, he was Chief Scientific Officer at Pacific Biosciences, the next-generation sequencing technology provider. Previously, Dr. Schadt was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. in Seattle, and before Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics from University of California, Davis, and his Ph.D. in bio-mathematics from University of California, Los Angeles (requiring Ph.D. candidacy in molecular biology and mathematics).